| Literature DB >> 26261802 |
Paulrasu Kodisundaram1, Arul Duraikannu2, Thirunavukkarasu Balasankar3, Pravin Sundarao Ambure4, Kunal Roy5.
Abstract
The current study highlights the in vitro antioxidant and antitumor activity of the previously-synthesized hydrazone derivatives against various free radicals and human cancer cell lines, respectively. The anticancer efficacies of the compound were tested by measuring cytotoxicity in cancer cell lines HeLa, A549, and non-cancerous NL20 cells. Compounds possessing electron-donor methoxy and methyl substitutions at the para position of the phenyl ring moiety showed a concentration dependent free radical scavenging effects. The free radical-scavenging potential of synthetic compounds 11 and 14 may have significant impact on the prevention of free radical-induced oxidative stress and carcinogenesis. The results from cytotoxicity and cell migration assay showed that the substitution of electron-withdrawing fluoro, chloro and bromo functional groups induced a significant (P< 0.001) loss of cell viability and inhibited the invasive potential of the human cancer cells. Additionally, these compounds showed significantly (P< 0.05) a less toxicity toward non-cancerous NL20 cells. Docking studies revealed interactions of compound 10 with p38α MAP kinase, which may be responsible of its anti-invasive and anti-proliferative effects.Entities:
Keywords: 3- azabicylonones; Antioxidant; anticancer; cytotoxicity; hydrazones
Year: 2015 PMID: 26261802 PMCID: PMC4499575
Source DB: PubMed Journal: Int J Mol Cell Med ISSN: 2251-9637
Fig. 1Synthesis of 2r,4c- diaryl -3-azabicyclo[3.3.1]nonan -9-one-4-methyl-1,2,3- thiadiazole-5-carbonyl hydrazones (9-15)
Fig. 2Numbering of the azabicycle [3.3.1] nonane
IC50 valve for free radical scavenging activity (µg/mL).
|
|
|
|
|
|
| ||
|---|---|---|---|---|---|---|---|
| Ascorbic acid | 7.50 | 9.52 | 10.19 | 12.03 | 13.32 | ||
| 9 | 9.12 | 9.98 | 11.46 | 12.68 | 14.01 | ||
| 10 | 9.56 | 10.16 | 11.79 | 12.78 | 14.19 | ||
| 11 | 6.93 | 8.31 | 9.45 | 9.07 | 10.02 | ||
| 12 | 10.12 | 10.96 | 11.83 | 12.94 | 14.82 | ||
| 13 | 10.52 | 11.02 | 12.14 | 13.09 | 15.23 | ||
| 14 | 7.45 | 9.96 | 11.06 | 12.43 | 13.80 | ||
| 15 | 11.12 | 11.89 | 12.07 | 14.11 | 15.33 | ||
IC50 values were determined by plotting dose-response curves of radical scavenging activities vs the concentration of synthetic compounds using GraphPad Prism version 4.00 for Windows (GraphPad Software Inc., San Diego, CA).
IC50 valve for MTT assay (µmol)
|
|
|
|
|
|---|---|---|---|
| 9 | 9.91 | 11.28 | 12.35 |
| 10 | 4.41 | 6.61 | 12.36 |
| 11 | 10.27 | 12.56 | 13.45 |
| 12 | 4.43 | 6.60 | 8.63 |
| 13 | 4.48 | 4.61 | 8.36 |
| 14 | 10.01 | 12.43 | 13.02 |
| 15 | 10.03 | 12.56 | 13.25 |
IC50 values were determined by plotting dose-response curves of cytotoxic effects vs the concentration of synthetic compounds using GraphPad Prism version 4.00 for Windows (GraphPad Software Inc., San Diego, CA)
Fig. 3Antiproliferative effects of synthetic compounds 10, 12 and 13 at 8µM in HeLa A549 and NL20 cells by crystal blue staining method. * Significantly different from untreated control cells (P<0.05). ** Significantly different from untreated control cells (P<0.01). *** Significantly different from untreated control cells (P<0.001). Significantly different from untreated NL20 cells (P<0.05). Significantly different from untreated control cells (P<0.001).
Fig. 4Anti-invasive potential of synthetic compounds 10, 12 and 13 (8 μM) by cell migration assay. * Significantly different from untreated control cells (P<0.05
The docking score and interactions (hydrogen bond and π-π interactions) for the synthesized compounds
|
|
|
|
|
|---|---|---|---|
|
| -6.76 | Asp-168 | Lys 53, Arg 67 |
|
| -6.70 | Asp-168 | Arg 67 |
|
| -4.30 | Asp-168 | His 148, Arg 67 |
|
| -5.29 | Asp-168 | - |
|
| -4.52 | Asp-168 | His 174, Arg 67 |
|
| -4.69 | Met-109 | Phe 169 |
|
| -5.19 | Asp-168 | Arg 67 |
Fig. 5The interaction diagram showing hydrogen bonds and pi-pi interaction of (A) co-crystal ligand and (B) synthesized compound 10 with the active site of p38α MAP kinase